FUSN — Fusion Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.82bn
- $1.62bn
- $2.07m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.2 | -78.3 | -81 | -87.6 | -94.9 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -0.817 | 42.9 | 20.3 | 12.9 | 12.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 3.08 | 5.74 | -14.6 | 3.66 | -1.32 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -13.7 | -29.8 | -75.7 | -73.3 | -81.8 |
Capital Expenditures | -0.456 | -1.12 | -1.49 | -2.14 | -3.89 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -209 | 39.3 | 25.2 | -38.9 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.456 | -210 | 37.8 | 23.1 | -42.8 |
Financing Cash Flow Items | — | -4.57 | -0.275 | 0 | -4.03 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 52.2 | 266 | 0.347 | 40.7 | 142 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 38 | 25.3 | -37.6 | -9.46 | 17.4 |